Multiple Sclerosis (MS) Drug Market

Wall Street Journal  Oct 8  Comment 
Roche’s experimental drug proved effective in three late-stage studies against multiple sclerosis, potentially heralding an important new treatment option for the debilitating disease.  Oct 8  Comment 
BASEL (dpa-AFX) - Novartis (NVS) announced a new analysis from the phase III FREEDOMS and FREEDOMS II trials reinforcing the long-term efficacy profile of Gilenya or fingolimod. The analysis evaluated the proportion of Gilenya patients with...  Oct 7  Comment 
WESTON (dpa-AFX) - Biogen (BIIB) announced it will present new data that reinforce the efficacy and safety profile of TECFIDERA (dimethyl fumarate) in a broad range of people with relapsing-remitting multiple sclerosis. The company said the new...
Motley Fool  Oct 5  Comment 
Positive patent news on its multiple sclerosis drug Amypra is boosting shares.
FiercePharma  Sep 30  Comment 
Roche's experimental therapy, ocrelizumab, recently posted positive Phase III data in patients with primary progressive multiple sclerosis, a less common form of the disease--affecting about 10% to 20% of sufferers--that right now remains untreated.
FierceBiotech  Sep 28  Comment 
An in-development drug from Roche performed well against a hard-to-treat form of multiple sclerosis in what the company says is a Phase III first that could shake up a $20 billion market.
Benzinga  Sep 28  Comment 
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) of once-daily COPAXONE® (glatiramer acetate injection) 20mg injection for the...
Benzinga  Sep 21  Comment 
India Globalization Capital, Inc. (IGC) announces that the company applied for a provisional patent based on a novel therapy that uses cannabinoid extracts from the cannabis plant for the treatment of cachexia. Cachexia is a condition that...


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki